• 1. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548
• 2. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 3. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 4. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 5. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527

Research Briefing on 2-(1-Methylpyrrolidin-3-yl)ethan-1-amine (CAS: 774213-88-6) in Chemical Biology and Pharmaceutical Applications

The compound 2-(1-Methylpyrrolidin-3-yl)ethan-1-amine (CAS: 774213-88-6) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This briefing synthesizes the latest findings on this molecule, focusing on its synthesis, biological activity, and emerging roles in drug discovery.

Recent studies have highlighted the versatility of 2-(1-Methylpyrrolidin-3-yl)ethan-1-amine as a key intermediate in the synthesis of novel bioactive compounds. Its pyrrolidine scaffold, combined with the flexible ethylamine side chain, makes it an attractive building block for the development of central nervous system (CNS) targeting drugs. A 2023 publication in the Journal of Medicinal Chemistry demonstrated its utility in creating potent sigma-1 receptor ligands with potential applications in neuropathic pain management.

Advanced analytical techniques, including X-ray crystallography and NMR spectroscopy, have been employed to characterize the molecular structure and conformational dynamics of 2-(1-Methylpyrrolidin-3-yl)ethan-1-amine. These studies reveal important insights into its stereochemical preferences and interactions with biological targets, providing a foundation for structure-activity relationship (SAR) optimization in drug design programs.

In pharmacological investigations, researchers have explored the compound's potential as a modulator of neurotransmitter systems. Preliminary in vitro studies indicate moderate affinity for dopamine and serotonin transporters, suggesting possible applications in mood disorder therapeutics. However, recent findings emphasize the need for careful optimization of its physicochemical properties to improve blood-brain barrier penetration and reduce off-target effects.

The synthetic accessibility of 2-(1-Methylpyrrolidin-3-yl)ethan-1-amine has been improved through novel catalytic methods. A 2024 report in Organic Process Research & Development described an efficient asymmetric synthesis route using chiral auxiliaries, achieving >95% enantiomeric excess. This advancement addresses previous challenges in obtaining optically pure forms of the compound for biological evaluation.

Emerging applications in radiopharmaceutical development have been reported, where 2-(1-Methylpyrrolidin-3-yl)ethan-1-amine serves as a precursor for PET tracer synthesis. Its ability to chelate certain metal ions while maintaining favorable pharmacokinetic properties makes it particularly valuable for imaging agent development targeting neurological disorders.

Safety and toxicological assessments of 2-(1-Methylpyrrolidin-3-yl)ethan-1-amine have progressed, with recent in vivo studies demonstrating favorable acute toxicity profiles at therapeutic doses. However, chronic exposure studies are still ongoing, and researchers caution about potential cardiovascular effects that may require structural modifications in clinical candidates derived from this scaffold.

Looking forward, the compound's unique combination of structural features continues to inspire innovative research directions. Current investigations are exploring its incorporation into multifunctional drug conjugates and its potential as a fragment in fragment-based drug discovery approaches. The growing body of research on 2-(1-Methylpyrrolidin-3-yl)ethan-1-amine (CAS: 774213-88-6) positions it as a promising chemical entity with diverse applications in modern pharmaceutical development.

• 137909-19-4(Pyrrolidine, 1-ethyl-3-hexadecyl-)
• 588672-46-2(PYRROLIDINE, 1-ETHYL-3-(2-METHYLPROPYL)-)
• 2162-83-6(1,3-diethylpyrrolidine)
• 137909-16-1(Pyrrolidine, 3-dodecyl-1-propyl-)
• 588672-42-8(Pyrrolidine, 1-ethyl-3-propyl- (9ci))
• 18707-40-9(Pyrrolidine, 1-(2-ethylhexyl)-)
• 588672-49-5(Pyrrolidine, 1-ethyl-3-(1-methylethyl)- (9ci))
• 137909-18-3(Pyrrolidine, 3-dodecyl-1-ethyl-)
• 588672-44-0(PYRROLIDINE, 1-ETHYL-3-PENTYL-)
• 574754-62-4(1-Azabicyclo[4.2.1]nonane, 6,7-dimethyl-)